Alamar Biosciences, Inc.

ALMR·NasdaqGS·Healthcare
Compare
27.39−2.83 (−9.36%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close30.22
Open28.02
Day range25.3229.08
52-week range18.8539.61
Off day high−5.80%
Off 52-week high−30.85%
Volume1.53M
Avg. volume (3M)563.79K
Market cap1.90B
EPS (TTM)-1.13
Forward P/E-65.88
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding69.39M
Short interest6.25% of float
Earnings dateNov 3, 2026
Analyst target35.40
Profit margin−49.45%

Against its peers

Compare in full ›
ALMR LAB NEOG CTKB TXG BIO
Market cap 1.90B 243.14M 2.72B 764.30M 8.80B 10.16B
P/E (TTM) — — — — — 48.2
Forward P/E -65.9 -61.6 27.7 84.0 880.7 39.0
Price/book 6.2 0.4 1.3 2.2 10.7 1.4
Dividend yield — — — — — —
1-year change +37.36% −46.49% +94.85% +48.63% +383.99% +20.93%
Today −9.36% +0.85% +2.98% −1.34% +3.42% +1.35%

The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.

Latest news

All ALMR news ›
Seeking Alpha··3 outletsPositive

Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Yuling Luo - Co-Founder, Chairman & CEOJustin McAnear - Chief Financial Officer Daniel Brennan - TD Cowen, Research DivisionPuneet Souda - Leerink Partners…

More from 2 other outlets
The Manila Times··2 outletsPositive

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended…

More from 1 other outlet
Alamar Biosciences··2 outletsPositive

Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

The study targets earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions including rare dementias FREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE)…

More from 1 other outlet

From the 4Search news index, newest first.

In the news

39mentions in 30 days
36with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 39 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance